4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $577.85M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.68M
Average 0.77M
FDMT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
4D Molecular Therapeutics, Inc.NASDAQ: FDMT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $11.69M fell 9.7% year over year, behind the -5.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 8.5% from the prior quarter. Over 3 fiscal years it compounded at +14.2% a year.
Context
- Selling, general & admin amounted to 57.6% of revenue in FY2025, down 125831.6 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $3.64B (+7311.3%) for the fiscal year ending Dec 2026, a step up from the +5.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.69M-8.5% QoQ
- Last fiscal yearDec 2025
- $49.06M+5.3% YoY
- LTMMar 2026
- $47.81M-5.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 49.06M USD
- Year-over-year change
- +5.3%
- 4-year CAGR
- +15.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.06M | +5.3% |
| FY2024 | 2024-12-31 | 46.58M | +27.6% |
| FY2023 | 2023-12-31 | 36.49M | +10.9% |
| FY2022 | 2022-12-31 | 32.91M | +17.5% |
| FY2021 | 2021-12-31 | 28.01M | — |
Selling, General & Admin vs competitors
How FDMT compares with its peers on the latest reported figures
- FDMT's LTM Mar 2026 selling, general & admin of $47.81M is the 5th highest of the 8 companies compared; the peer median is $52.46M.
- Its year-over-year change of -5.9% is the 7th highest of 8, against a peer median of +9.4%.
- Selling, general & admin amounts to 54.2% of revenue for FDMT, versus a peer median of 396.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $83.82M | +6.5% | -1.0% | 95.4% | |
| LTM Mar 2026 | $73.88M | +132.8% | +55.6% | 508.1% | |
| LTM Mar 2026 | $71.65M | +50.0% | +6.1% | 396.0% | |
| LTM Mar 2026 | $52.46M | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $47.81M | -5.9% | +14.2% | 54.2% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M | -13.0% | +55.9% | — |
| LTM Mar 2026 | $29.24M | +9.4% | -8.0% | 654.9% | |
| Peer median (excluding FDMT) | $52.46M | +9.4% | +6.1% | 396.0% | |
Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.04M | 3.13M | 20.72M | 37K | 85.21M |
| Cost of Revenue | 61.36M | 80.25M | 97.1M | 141.3M | 7.63M |
| Gross Profit | (43.32M) | (77.12M) | (76.37M) | (141.26M) | 77.58M |
| Gross Margin | -240.2% | -2464.8% | -368.5% | -381789.2% | 91.1% |
| Research & Development | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M |
| Selling, General & Admin | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| Operating Expenses | 28.01M | 32.91M | 36.49M | 46.58M | 237.13M |
| Depreciation & Amortization | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M |
| EBITDA | (69.79M) | (105.09M) | (96.63M) | (154.16M) | (132.48M) |
| EBITDA Margin | -386.9% | -3358.6% | -466.3% | -416656.8% | -155.5% |
| Operating Income | (71.33M) | (110.03M) | (112.87M) | (187.84M) | (159.55M) |
| Operating Margin | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Interest Income | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16K | 2.54M | 12.03M | 26.97M | 19.44M |
| Income Before Tax | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Pre-Tax Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Net Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (Basic) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| EPS (Diluted) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| Weighted Avg Shares | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
| Weighted Avg Shares (Diluted) | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Intrinsic Alpha fair value
Locked
Current Price
$10.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.